These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28387904)

  • 1. Study on correlation between PKIB and pAkt expression in breast cancer tissues.
    Zhang JB; Song W; Wang YY; Liu MG; Sun MM; Liu H
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1264-1269. PubMed ID: 28387904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype.
    Dabanaka K; Chung S; Nakagawa H; Nakamura Y; Okabayashi T; Sugimoto T; Hanazaki K; Furihata M
    Med Mol Morphol; 2012 Dec; 45(4):229-33. PubMed ID: 23224602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Invasion and Metastasis by mPRα Through the PI3K/Akt Signaling Pathway.
    Wu X; Sun L; Wang X; Su P; Li Z; Zhang C; Wang Y; Gao P; Ma R
    Pathol Oncol Res; 2016 Jul; 22(3):471-6. PubMed ID: 26608797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
    Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
    Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
    Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
    Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
    Payandeh M; Sadeghi M; Sadeghi E; Madani SH
    Asian Pac J Cancer Prev; 2016; 17(3):1261-4. PubMed ID: 27039757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
    Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.